Pharma DECODED
Latest edition: 13 May 2024
Share newsletter
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Spotlight
RAPT terminates Phase II trials for lead candidate following clinical hold
RAPT is closing two Phase II trials for Rapt’s lead candidate, zelnecirnon, three months after the FDA placed a clinical hold on them.
Latest news
Dementia Action Week 2024: the future of Alzheimer's diagnostics
As the debate over using tau levels to guide patient treatment persists, the landscape for Alzheimer’s diagnostics continues to move ahead.
Pipeline Moves: Phase III completion for Corcept's relaorilant
The Clinical Trials Arena team evaluates assets in oncology and metabolic disorders.
Cardurion's PDE9 inhibitor increases cGMP in Phase IIa heart failure trial
Caudrion said the Phase IIa trial has proved that targeting PDE9 activates the NP signalling pathway.
EU-X-CT project to clarify cross-border trial access in Europe
Currently, there is no legislation or guidance to tell those in the industry how to run cross-border trials in Europe.
Ten children born deaf can now hear after Refreshgene trial
Refreshgene announced data at the ASCGT Conference 2024 where Regeneron also boasted positive data in a gene therapy hearing loss trial.
In our previous edition
Pharma Decoded
Takeda tackles $900m restructuring plan after generics hurt annual profits
10 May 2024
Pharma Decoded
ESCMID 2024: Emerging bacterial infections in neonates and children
09 May 2024
Pharma Decoded
AstraZeneca to withdraw Covid-19 vaccine globally
08 May 2024
Still looking?
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Explorer
Access more premium companies when you subscribe to Explorer